PUORRO GERARD E 4

Accession 0001178913-10-000269

CIK 0000793279other

View on SEC.gov Company Profile

Filed

Feb 1, 7:00 PM ET

Accepted

Feb 2, 5:12 PM ET

Size

32.8 KB

Accession

0001178913-10-000269

Insider Transaction Report

Form 4

Period: 2010-01-05

CANDELA CORP /DE/CLZR

PUORRO GERARD E

DirectorPresident & CEO

Transactions

Disposition to Issuer
Stock Appreciation Rights (right to buy)
2010-01-05−50,000→ 0 total
Exercise: $0.41Exp: 2019-01-19→ Common Stock, $0.01 par value per share (50,000 underlying)
Disposition to Issuer
Non-Qualified Stock Option (right to buy)
2010-01-05−20,000→ 0 total
Exercise: $9.50Exp: 2015-02-11→ Common Stock, $0.01 par value per share (20,000 underlying)
Disposition to Issuer
Non-Qualified Stock Option (Right to Buy)
2010-01-05−20,850→ 0 total
Exercise: $11.96Exp: 2014-01-26→ Common Stock, $0.01 par value per share (20,850 underlying)
Disposition to Issuer
Incentive Stock Option (Right to Buy)
2010-01-05−858→ 0 total
Exercise: $11.98Exp: 2014-01-29→ Common Stock, $0.01 par value per share (858 underlying)
Disposition to Issuer
Stock Appreciation Rights (right to buy)
2010-01-05−100,000→ 0 total
Exercise: $11.53Exp: 2017-04-03→ Common Stock, $0.01 par value per share (100,000 underlying)
Disposition to Issuer
Non-Qualified Stock Option (Right to Buy)
2010-01-05−29,142→ 0 total
Exercise: $11.98Exp: 2014-01-29→ Common Stock, $0.01 par value per share (29,142 underlying)
Disposition to Issuer
Stock Appreciation Rights (right to buy)
2010-01-05−80,000→ 0 total
Exercise: $15.33Exp: 2016-01-30→ Common Stock, $0.01 par value per share (80,000 underlying)
Disposition to Issuer
Incentive Stock Option (Right to Buy)
2010-01-05−9,150→ 0 total
Exercise: $11.96Exp: 2014-01-26→ Common Stock, $0.01 par value per share (9,150 underlying)
Disposition to Issuer
Common Stock
2010-01-05−242,000→ 0 total
Disposition to Issuer
Stock Appreciation Rights (right to buy)
2010-01-05−120,000→ 0 total
Exercise: $4.29Exp: 2018-01-25→ Common Stock, $0.01 par value per share (120,000 underlying)
Disposition to Issuer
Incentive Stock Option (Right to Buy)
2010-01-05−8→ 0 total
Exercise: $10.35Exp: 2014-08-23→ Common Stock, $0.01 par value per share (8 underlying)
Disposition to Issuer
Non-Qualified Stock Option (right to buy)
2010-01-05−69,992→ 0 total
Exercise: $10.35Exp: 2014-08-23→ Common Stock, $0.01 par value per share (69,992 underlying)

Footnotes (12)

[F1]These shares were disposed of pursuant to a merger agreement between the Issuer and Syneron Medical Ltd. "Syneron" in exchange for 70,446 ordinary shares of Syneron having a market value of $10.39 per share at the close of trading on the effective date of the merger.
[F10]The non-qualified stock options, which were exercisable in three annual installments beginning on January 26, 2005, were vested in full and assumed by Syneron as a result of the merger and replaced with non-qualified stock options to purchase 6,069 ordinary shares of Syneron at an exercise price of $41.09 per share.
[F11]The non-qualified stock options, which were exercisable in four annual installments beginning on January 29, 2005, were vested in full and assumed by Syneron as a result of the merger and replaced with non-qualified stock options to purchase 8,483 ordinary shares of Syneron at an exercise price of $41.16 per share.
[F12]The incentive stock options, which were exercisable in one installment on January 29, 2008, were vested in full and assumed by Syneron as a result of the merger and replaced with incentive stock options to purchase 249 ordinary shares of Syneron at an exercise price of $41.16 per share.
[F2]The stock-settled stock appreciation rights, which were exercisable in two equal installments beginning on January 19, 2010, were vested in full and assumed by Syneron as a result of the merger and replaced with stock-settled stock appreciation rights to purchase 14,555 ordinary shares of Syneron at an exercise price of $1.41 per share.
[F3]The stock-settled stock appreciation rights, which were exercisable in four equal installments beginning on January 25, 2009, were vested in full and assumed by Syneron as a result of the merger and replaced with stock-settled stock appreciation rights to purchase 34,932 ordinary shares of Syneron at an exercise price of $14.74 per share.
[F4]The stock-settled stock appreciation rights, which were exercisable in four equal installments beginning on April 3, 2008, were vested in full and assumed by Syneron as a result of the merger and replaced with stock-settled stock appreciation rights to purchase 29,110 ordinary shares of Syneron at an exercise price of $39.61 per share.
[F5]The stock-settled stock appreciation rights, which were exercisable in four equal installments beginning on January 30, 2007, were vested in full and assumed by Syneron as a result of the merger and replaced with stock-settled stock appreciation rights to purchase 23,288 ordinary shares of Syneron at an exercise price of $52.67 per share.
[F6]The non-qualified stock options, which were immediately exercisable on November 2, 2005, were vested in full and assumed by Syneron as a result of the merger and replaced with non-qualified stock options to purchase 5,822 ordinary shares of Syneron at an exercise price of $32.64 per share.
[F7]The incentive stock options, which were exercisable in four annual installments beginning on August 23, 2005, were vested in full and assumed by Syneron as a result of the merger and replaced with incentive stock options to purchase 2 ordinary shares of Syneron at an exercise price of $35.56 per share.
[F8]The non-qualified stock options, which were exercisable in four equal annual installments beginning on August 23, 2005, were vested in full and assumed by Syneron as a result of the merger and replaced with non-qualified stock options to purchase 20,374 ordinary shares of Syneron at an exercise price of $35.56 per share.
[F9]The incentive stock options, which were exercisable in four annual installments beginning on January 26, 2005, were vested in full and assumed by Syneron as a result of the merger and replaced with incentive stock options to purchase 2,663 ordinary shares of Syneron at an exercise price of $41.09 per share.

Documents

1 file

4
a1007841_ex.xmlPrimary

Issuer

CANDELA CORP /DE/

CIK 0000793279

→

Entity typeother

Related Parties

filerCIK 0001236578

Filing Metadata

Form type: 4
Filed: Feb 1, 7:00 PM ET
Accepted: Feb 2, 5:12 PM ET
Size: 32.8 KB

View on SEC.gov